HIGHLIGHTS
SUMMARY
Sulfadoxine-pyrimethamine (SP) remained clinically effective to treat uncomplicated malaria until the early 2000s, but subsequent clinical studies performed after 2003 showed a rapidly declining efficacy of amodiaquine and sulfadoxine-pyrimethamine monotherapies, as supported by in_vitro drug sensitivity assays and molecular markers of resistance. Based on the results of randomized therapeutic efficacy studies conducted in 2004 in southern Republic of the Congo, artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) were selected by the Congolese Ministry of Health and Population as firstand second-line drugs for the treatment of uncomplicated malaria, respectively. The two studies . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.